NCT06509997View on ClinicalTrials.gov

A Phase II Study of Anti-EGFR Antibody-drug Conjugate (ADC) Combine With CDK4/6 Inhibitors Posterior Line in the Treatment of Recurrent/Metastatic CDKN2A Gene Variant Head and Neck Squamous Cell Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

MRG003 combined with Dalpicicilip

MRG003, intravenous infusion, D1, once every 3 weeks; Dalpicicilip, taking orally, D1-21, once every 4 weeks, maintain use until progression or emergence of intolerable toxicity.

All Listed Sponsors
lead

Lei Liu

OTHER